|
|
|
|
Vol. 301, Issue 1, 284-292, April 2002
Program in Clinical and Experimental Therapeutics, University of
Georgia College of Pharmacy, Medical College of Georgia, Augusta,
Georgia (A.V.T.); Alzheimer's Research Center and Department of
Pharmacology and Toxicology, Medical College of Georgia, Augusta,
Georgia (A.V.T., J.J.B.); Department of Veterans Affairs Medical
Center, Augusta, Georgia (A.V.T., J.J.B.); and Merck Research
Laboratories, La Jolla, California (V.B.R., F.M.)
Nicotine, a nonselective ligand for nicotinic acetylcholine
receptors (nAChRs), has been shown to improve attention and reduce distractibility in humans. Although the numerous side effects induced
by nicotine prevent its use as a therapeutic agent, it is hypothesized
that subtype-selective nAChR ligands may offer a potential therapeutic
benefit to humans with attention deficits. In this study, we evaluated
the attention-enhancing properties of
(±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol
hydrochloride (SIB-1553A), a ligand selective for neuronal nAChRs with
predominant activity at the human
4 subtype. SIB-1553A was evaluated
in a test of attention (i.e., five-choice serial reaction time task or
SRTT) and distractibility (i.e., delayed matching to sample task with
distractor or DMTS-D) in adult rats and monkeys, respectively. SIB-1553A did not improve SRTT performance in normal rats, but reversed
deficits induced by the N-methyl-D-aspartate
(NMDA) antagonist dizocilpine. In the DMTS-D, SIB-1553A improved
accuracy across several doses at the short delay intervals, which were
affected most by distracting stimuli in adult monkeys. Subsequent
testing with optimal doses for each monkey was also associated with
significant improvements in DMTS-D accuracy at short delays, indicating
the reproducibility of the drug effect. In both species, SIB-1553A had
no significant effects on latencies for sample or choice selection and
was not associated with adverse effects at efficacious doses. Although
it remains to be further demonstrated, SIB-1553A may act through
combined nicotinic and non-nicotinic mechanisms. Collectively, the
present data suggest that in specific conditions SIB-1553A may improve
certain aspects of attentional function in young adult rats and
nonhuman primates without adverse side effects.
This article has been cited by other articles:
![]() |
L. Azam and J. M. McIntosh Characterization of Nicotinic Acetylcholine Receptors That Modulate Nicotine-Evoked [3H]Norepinephrine Release from Mouse Hippocampal Synaptosomes Mol. Pharmacol., September 1, 2006; 70(3): 967 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Buccafusco Neuronal Nicotinic Receptor Subtypes: DEFINING THERAPEUTIC TARGETS Mol. Interv., October 1, 2004; 4(5): 285 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Terry Jr and J. J. Buccafusco The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 821 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Schneider, J. P. Tinker, F. Menzaghi, and G. K. Lloyd The Subtype-Selective Nicotinic Acetylcholine Receptor Agonist SIB-1553A Improves Both Attention and Memory Components of a Spatial Working Memory Task in Chronic Low Dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Monkeys J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 401 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Popke From Anticholinesterase Toxicity to Alzheimer's Disease: Important Interactions of Cholinergic and NMDA Receptor Systems Toxicol. Sci., April 1, 2003; 72(2): 185 - 187. [Abstract] [Full Text] [PDF] |
||||